drugset / Trial / NCT05995366

A Study to Assess the Mass Balance of [14C] ABBV-903 in Healthy Male Participants Following Single Oral Dose Administration

NCT05995366 ↗

Phase 1 Completed 7 enrolled AbbVie
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to evaluate the mass balance and safety of \[14C\] ABBV-903 in healthy male volunteers following a single oral dose administration.

Timeline

Start
2023-08-18
Primary completion
2023-10-13
Completion
2023-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-903 Unknown — Oral

Indications

No indication recorded.